Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis

This was a post-hoc analysis of patient-reported outcomes from the LIBERTY AD PEDS randomized, double-blind, placebo-controlled, phase III trial of dupilumab + topical corticosteroids (TCS) in 367 children aged 6–11 years with severe atopic dermatitis (AD). At week 16, significantly more patients treated with dupilumab vs. placebo achieved a Patient-Oriented Eczema Measure (POEM) score of 0/1 (‘clear skin’/‘almost clear skin’), and significantly more reported Children’s Dermatology Life Quality Index (CDLQI) scores of 0/1 (‘no effect on life’). Significantly more patients achieved a minimal clinically important difference (≥ six-point reduction) in POEM and in CDLQI. Dupilumab (vs. placebo) + TCS resulted in clinically meaningful improvements in patients’ assessment of AD symptoms and quality of life.